HMG-CoA Reductase Inhibitor
Estarol™
(Atorvastatin)
Reduces LDL-C and triglycerides, modestly raises HDL-C; used for primary and secondary prevention.
Strengths: 20 mg, 40 mg tablets
We develop and manufacture prescription medicines across cardiovascular, metabolic, gastrointestinal, anti-infective, pain, neurology and specialty categories. Facilities operate under ISO 9001/14001 and WHO-GMP aligned systems to deliver consistent quality and reliable supply.
Lipid management and blood-pressure control with well-established molecules.
(Atorvastatin)
Reduces LDL-C and triglycerides, modestly raises HDL-C; used for primary and secondary prevention.
Strengths: 20 mg, 40 mg tablets
(Ezetimibe + Atorvastatin)
Blocks intestinal cholesterol absorption and hepatic synthesis for tougher LDL-C targets.
Strengths: 10/10 mg, 10/20 mg
(Rivaroxaban)
Oral anticoagulant indicated for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation..
Strength: 20 mg tablets
(Simvastatin)
Oral statin indicated for the reduction of elevated LDL-cholesterol and triglycerides, and for cardiovascular risk reduction in appropriate patients.
Strength: 20 mg tablets
(Irbesartan)
ARB for hypertension; kidney protection benefits in diabetic nephropathy noted in guidelines.
Strengths: 150 mg, 300 mg tablets
(Irbesartan / Hydrochlorothiazide)
Fixed-dose combination of an angiotensin II receptor blocker and thiazide diuretic for enhanced blood pressure control in patients requiring dual therapy.
Strengths: 150/12.5 mg, 300/25 mg tablets
(Chlorthalidone + Amlodipine + Telmisartan)
Triple-agent tablet (diuretic + CCB + ARB) for patients needing intensive blood-pressure control.
Strengths: Per local registration
(Chlorthalidone + Telmisartan)
Fixed-dose combination for patients requiring additional blood-pressure reduction.
Strengths: Per local registration
(Metoprolol Succinate ER + Telmisartan)
Combines heart-rate control with RAAS blockade for comprehensive BP management.
Strengths: Per local registration
(Rosuvastatin + Aspirin + Clopidogrel)
Triple regimen supporting lipid control and antiplatelet protection per local guidelines.
Strengths: Rosuvastatin 20 mg; others per local registration
(Rosuvastatin)
High-potency statin for LDL-C reduction and risk lowering in appropriate patients.
Strengths: 20 mg tablets
(Icosapentanoato de Etilo)
Highly purified EPA for triglyceride reduction and CV risk lowering in select high-risk patients.
Strengths: 1 g soft capsules
(Glyceryl Trinitrate)
Sublingual nitrate formulation indicated for the rapid relief of acute angina pectoris attacks.
Strength: 0.6 mg sublingual tablets
DPP-4 inhibitors for type 2 diabetes, to be used with diet and exercise ± background therapy.
(Linagliptin)
Raises incretin activity to support glucose-dependent insulin release and lower glucagon.
Strengths: 5 mg tablets
(Sitagliptin)
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Strengths: 100 mg tablets
(Metformina)
First-line oral agent for type 2 diabetes; improves insulin sensitivity and lowers hepatic glucose output.
Strengths: 1 g tablets
(Empagliflozina)
Reduces renal glucose reabsorption, with demonstrated CV and renal outcome benefits in T2DM patients.
Strengths: 25 mg tablets
(Sitagliptina / Metformina)
Fixed-dose combination for patients requiring dual therapy to achieve glycemic targets.
Strengths: 50/1000 mg tablets
(Empagliflozin + Linagliptin)
Fixed-dose combo for adults with type 2 diabetes to improve glycemic control alongside diet and exercise.
Strengths: Per local registration
Acid suppression with a well-established proton-pump inhibitor.
(Esomeprazole)
For GERD, erosive esophagitis healing/maintenance, and other acid-related conditions per label.
Strengths: 20 mg, 40 mg tablets
(NaCl • KCl • Sodium Citrate • Anhydrous Glucose)
Powder for oral solution to treat and prevent dehydration associated with diarrhea or heat stress; WHO-style ORS electrolyte profile.
Format: Sachets (orange flavor)
(Ranitidine)
Injectable H2 receptor blocker for rapid reduction of gastric acid secretion in acute gastrointestinal conditions when parenteral therapy is required.
Strength: 50 mg / 2 mL ampoules
(Rabeprazole Sodium, EC / Domperidone, SR)
Dual-action capsules for acid control and relief of reflux-related symptoms per local labeling.
Strengths: Per local registration
(Pantoprazole, Gastro-resistant / Domperidone, Prolonged-release)
Acid suppression plus prokinetic support for GERD and dyspepsia where appropriate.
Strengths: Per local registration
COX-2 selective option where an NSAID is indicated and appropriate.
(Etoricoxib)
For symptomatic relief in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and gout flares.
Strengths: 120 mg tablets
(Dexamethasone)
Systemic corticosteroid injection used for anti-inflammatory and immunosuppressive therapy in acute conditions requiring parenteral administration.
Strength: 8 mg / 2 mL ampoules
(Diclofenac Sodium)
Injectable NSAID for rapid relief of acute pain and inflammation when oral administration is not suitable.
Strength: 75 mg / 3 mL ampoules
(Tramadol Hydrochloride)
Parenteral analgesic indicated for the management of moderate to severe pain where opioid-class treatment is appropriate.
Strength: 100 mg / 2 mL ampoules
(Metamizole Sodium)
Injectable non-opioid analgesic and antipyretic for acute pain and high fever, administered under medical supervision.
Strength: 1 g / 2 mL ampoules
5-alpha reductase inhibition for BPH where appropriate.
(Dutasteride)
Oral therapy for benign prostatic hyperplasia, reducing prostate volume and improving urinary flow by inhibiting dihydrotestosterone synthesis.
Strength: 0.5 mg capsules
Evidence-based antibiotics with clear dosing and quality controls.
(Levofloxacina)
Broad-spectrum antibiotic used as per antimicrobial stewardship and local guidelines.
Strengths: 750 mg film-coated tablets
(Ceftriaxone)
Broad-spectrum parenteral antibiotic used for severe infections, including respiratory, urinary, and systemic infections, according to local antimicrobial guidelines.
Strength: 1 g vials (powder for injection)
Central-acting agents for neuropathic pain and adjunct seizure control.
(Pregabalina)
For neuropathic pain conditions and as adjunct therapy for partial-onset seizures where indicated.
Strengths: 150 mg capsules
Core acetaminophen line, with combos for symptom clusters.
(Paracetamol / Acetaminophen)
Ready-to-use intravenous solution for short-term treatment of pain and fever when oral administration is not appropriate.
Strength: 1000 mg / 100 mL single-dose vial
(Paracetamol / Acetaminophen)
Reduces fever and relieves mild to moderate pain.
Strengths: 500 mg tablets
(Aceclofenac + Paracetamol + Serratiopeptidase)
For inflammatory pain where an NSAID with analgesic and anti-edema enzyme support is appropriate.
Strengths: Per local registration
(Aceclofenac + Paracetamol + Thiocolchicoside)
Combines analgesia with a centrally acting muscle relaxant for painful muscle spasm.
Strengths: Per local registration
(Diclofenac Potassium + Paracetamol + Chlorzoxazone)
Targets acute musculoskeletal pain with added muscle-relaxant support.
Strengths: Per local registration
(Ibuprofen + Paracetamol)
Dual-action analgesic pairing for short-term relief of moderate pain and fever.
Strengths: Per local registration
(Trypsin + Bromelain + Rutoside Trihydrate)
Enzyme-flavonoid combination used as an adjunct for edema and inflammation in soft-tissue injury.
Strengths: Per local registration
Discuss dossier availability, tech transfer, and packaging options across our portfolio.
Contact Manufacturing About Crassula